Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances
Biochemical Pharmacology · 2026
DOI: 10.1016/j.bcp.2026.118331 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2026. Verfasst von Vivek Uttam und 5 weiteren Autor:innen. Beteiligte Einrichtung: Non-coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, 151401 Bathinda, Punjab, India. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Neoplasms, Translational Research, Biomedical. Die Arbeit nennt 225 Literaturangaben. Gefördert von: Arthritis National Research Foundation, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Breast, ovarian, cervical, and endometrial malignancies remain major causes of cancer-related morbidity and mortality due to metastatic progression, immune evasion, and the limited durability of therapeutic responses. Although immune checkpoint inhibitors have improved outcomes in selected patients, their efficacy is frequently constrained by profoundly immunosuppressive tumor microenvironments (TMEs). This review summarizes the molecular mechanisms driving immune resistance across these malignancies and highlights emerging strategies to improve immunotherapeutic efficacy. The roles of classical and emerging immune checkpoints, including Programmed cell death receptor 1 (PD-1), Programmed cell death-ligand 1 (PD-L1), T-cell immunoglobulin and mucin domain 3 (TIM-3), Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), Lymphocyte-activation gene 3 (LAG-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), V-domain Ig suppressor of T-cell activation (VISTA), and Siglec-mediated glyco-checkpoints, are discussed in the context of T-cell dysfunction and tumor immune escape. Mechanisms regulating immune cell infiltration, including chemokine signaling, stromal remodeling, and cytokine networks, are also examined for their contributions to immune exclusion or activation within the TME. Furthermore, metabolic reprogramming pathways, including lactate accumulation, adenosine signaling, and tryptophan catabolism, are evaluated for their roles in suppressing antitumor immunity and promoting tumor progression. The therapeutic potential of epigenetic modulation to restore antigen presentation, interferon signaling, and immune responsiveness is also highlighted. Finally, advances in antibody-drug conjugates, cancer vaccines, and adoptive cellular therapies are discussed as promising strategies that combine targeted cytotoxicity with immune activation. Overall, these insights support biomarker-driven combination therapies to overcome immune resistance and improve durable clinical outcomes in breast and gynaecological malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Non-coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, 151401 Bathinda, Punjab, India.
- Department of Pharmacology, National University of Singapore, 16 Medical Drive, Singapore, 117600 Singapore. Electronic address: phcgs@nus.edu.sg.
- Non-coding RNA and Cancer Biology Lab, Department of Zoology, Central University of Punjab, Ghudda, 151401 Bathinda, Punjab, India. Electronic address: aklankjain@gmail.com.
Förderung
- Arthritis National Research Foundation
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Uttam, V., Daffara, S., Singh, S., Kaur, R., Sethi, G., & Jain, A. (2026). Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2026.118331
Vancouver
Uttam V, Daffara S, Singh S, Kaur R, Sethi G, Jain A. Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances. Biochemical Pharmacology. 2026. doi:10.1016/j.bcp.2026.118331
BibTeX
@article{Uttam2026,
author = {Uttam, Vivek and Daffara, Sia and Singh, Sandeep and Kaur, Ravneet and Sethi, Gautam and Jain, Aklank},
title = {Overcoming immune resistance through tumor microenvironment reprogramming: Emerging immunotherapeutic strategies and translational advances},
journal = {Biochemical Pharmacology},
year = {2026},
doi = {10.1016/j.bcp.2026.118331}
}
EUVIMED